Brokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) PT at $26.63

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has been given a consensus rating of “Buy” by the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $26.63.

Several equities research analysts have commented on the stock. Chardan Capital reiterated a “buy” rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday. Robert W. Baird dropped their target price on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday. Finally, Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price target on the stock.

Institutional Trading of EyePoint Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. acquired a new stake in shares of EyePoint Pharmaceuticals during the fourth quarter worth about $23,705,000. TCG Crossover Management LLC raised its holdings in EyePoint Pharmaceuticals by 287.3% during the 4th quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company’s stock worth $26,614,000 after buying an additional 2,650,000 shares during the period. Adage Capital Partners GP L.L.C. raised its holdings in EyePoint Pharmaceuticals by 51.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company’s stock worth $42,838,000 after buying an additional 1,958,580 shares during the period. Federated Hermes Inc. lifted its stake in EyePoint Pharmaceuticals by 92.7% in the fourth quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company’s stock valued at $27,620,000 after buying an additional 1,783,765 shares in the last quarter. Finally, Suvretta Capital Management LLC boosted its holdings in shares of EyePoint Pharmaceuticals by 31.1% in the fourth quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company’s stock valued at $50,534,000 after buying an additional 1,607,268 shares during the period. 99.41% of the stock is owned by institutional investors.

EyePoint Pharmaceuticals Stock Up 4.5 %

EyePoint Pharmaceuticals stock opened at $7.13 on Monday. EyePoint Pharmaceuticals has a 52-week low of $5.54 and a 52-week high of $26.06. The firm has a market capitalization of $486.63 million, a price-to-earnings ratio of -3.57 and a beta of 1.41. The firm has a 50-day moving average price of $7.25 and a two-hundred day moving average price of $8.45.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). The business had revenue of $11.60 million for the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. Research analysts expect that EyePoint Pharmaceuticals will post -2.13 earnings per share for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.